Melasma Clinical Trial
Official title:
Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion.
Hypothesis -
The developments of solar lentigine and melasma are due to mutations in keratinocytes that
drive the production and transfer of pigment from melanocytes to keratinocytes.
Aims -
1. Characterize and classify lentigines and mealsma from a clinical and physiological
point of view. This will help us to better understand the cellular processes leading to
the development of lentigines (also referred to as Senile or Solar Lentigo).
2. Proper characterization and classification of lentigines and melasma would facilitate
the development of models to study and find solutions to treat these lesions.
Hypothesis - The developments of solar lentigine and melasma are due to mutations in
keratinocytes that drive the production and transfer of pigment from melanocytes to
keratinocytes.
Methodology -
Patients, 21 - 80 year old, who have elected to undergo a plastic surgery will be enrolled.
Some patient information (i.e. age, sex, race, family history, life-style related to
sun-exposure) will be collected.
After surgery, hyper-pigmented spots will be excised and stored in individual containers for
subsequent experimental procedures.
Before surgery, the area containing the hyper-pigmented spots will be photographed using a
high resolution digital camera and assessed using optical probes (Spectrophotometer to
measure skin chromophores, mexameter to measure the melanin and erythema indexes and a
diffuse reflectance spectrometer to measure hemoglobin, deoxyhemoglobin and melanin).
After surgery, excised skin samples will be processed for histological assessments, others
for gene or protein expression analysis, and yet another group will be used to isolate
keratinocyte and melanocyte to further study their behavior and response to stimuli in
primary cultures.
Clinical assessment of Hyperpigmented lesions:
Lentigo Morphological assessment (before surgery)
1. Macules vary in color from yellow, light-brown to black, depending on under-lying skin
type
2. Size varies from 1mm to greater than 1 cm
3. Appear on sun-exposed areas (face, neck, etc)
Morphological assessment (before surgery)
1. Irregular light to dark brown to gray brown macules or patches on sun-exposed areas
2. When examine with Wood's lamp, melasma can be classified into 3 types, epidermal,
dermal, or mixed, based on intensity of pigments, in which epidermal melasma has darker
color than derma melasma. Mixed melasma has a mixture of both dark and light
pigmentations
3. Melanocytes in melasma lesion have an increase in the number of mitochondria, golgi
apparatus, rough ER, and ribosomes
Spectrophotometer will be used to measure the optical properties of spots and control areas
(without the spot)
Sample processing
1. RNA extraction
2. Histology
3. Isolation of Keratinocytes, and Melanocytes.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05013801 -
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
|
N/A | |
Recruiting |
NCT06174545 -
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
|
N/A | |
Completed |
NCT01695356 -
Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma
|
Phase 4 | |
Recruiting |
NCT06278948 -
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma
|
N/A | |
Not yet recruiting |
NCT05911698 -
Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.
|
N/A | |
Recruiting |
NCT05656833 -
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
|
N/A | |
Recruiting |
NCT04597203 -
Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial
|
N/A | |
Completed |
NCT02138539 -
Evaluation of an Herbal-Based De-Pigmenting System
|
Phase 4 | |
Recruiting |
NCT01661556 -
Clinical Trial of Hydroquinone Versus Miconazol in Melasma
|
Phase 4 | |
Completed |
NCT01001624 -
Melanil in the Treatment of Melasma
|
Phase 3 | |
Terminated |
NCT03415685 -
Lutronic PicoPlus Exploratory Clinical Trial
|
N/A | |
Recruiting |
NCT04765930 -
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
|
N/A | |
Completed |
NCT04137263 -
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
|
N/A | |
Recruiting |
NCT03686787 -
Oral Tranexamic Acid and Laser for Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05969587 -
Cysteamine Compared to Hydroquinone in Melasma
|
Phase 3 | |
Completed |
NCT00500162 -
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
|
Phase 4 | |
Completed |
NCT00472966 -
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
|
Phase 4 | |
Completed |
NCT05884151 -
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
|
Phase 1 | |
Completed |
NCT05887219 -
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
|
Phase 1 | |
Recruiting |
NCT03308370 -
Platelet Rich Plasma in Treatment of Melasma
|
Phase 3 |